{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-110385","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.599063+00:00","generated_at":"2026-05-16T19:50:31.545417+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adial reports Q3 net loss $1.8M, cash $4.6M; FDA provides Phase 3 guidance for AD04","bullets":["Net loss $1.8M for Q3 2025 vs $2.2M in Q3 2024; R&D expenses down 50% YoY.","Cash and equivalents $4.6M at Sep 30, 2025; runway into Q2 2026.","Successful End of Phase 2 meeting with FDA; obtained guidance on Phase 3 design for AD04 (AUD).","Analytical validation of cheek swab test with Genomind for biomarker-positive patients; FDA confirmed NSR, no IDE needed.","Patent protection extended to at least 2045 via provisional patent update filed July 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-110385","json":"https://secwatch.observer/filing/0001213900-25-110385.json","markdown":"https://secwatch.observer/filing/0001213900-25-110385.md","text":"https://secwatch.observer/filing/0001213900-25-110385.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025110385/0001213900-25-110385-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025110385/ea0265418-8k_adial.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:50:31.545417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}